Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Published in: Pathology & Oncology Research 4/2009

01-12-2009 | Original Paper

An Immunohistochemical Study of Colon Adenomas and Carcinomas: E-cadherin, Syndecan-1, Ets-1

Authors: Zsuzsanna Pap, Zoltán Pávai, Lóránd Dénes, Ilona Kovalszky, János Jung

Published in: Pathology & Oncology Research | Issue 4/2009

Login to get access

Abstract

It is thought that dysregulation of E-cadherin, syndecan-1 (CD138) and Ets-1 is involved in carcinoma development. E-cadherin is an important epithelial cell adhesion molecule; syndecan-1 (CD138) is a regulatory proteoglycan in both cell-cell and cell-matrix adhesion and Ets-1 is a proto-oncogene and transcription factor, which takes part in extracellular matrix remodeling. Our goal was to study the changes in the expression of these molecules during colon carcinoma development and progression. We tested 117 colon adenomas and 149 de novo and ex adenoma carcinomas of the colon, using the Ultravision Polymer system. The positive reaction rate was 100% for E-cadherin, 98.3% for syndecan-1 and 22.4% for Ets-1 in adenomas, while in carcinomas it was 88.5%, 62.4% and 56.3% respectively. We found decreasing expression of E-cadherin and syndecan-1 throughout colon carcinoma progression and an opposite regulation for the Ets-1 protein. Decrease in expression of syndecan-1 is more pronounced in carcinomas compared to E-cadherin. De novo carcinomas have lower E-cadherin and syndecan-1 expression, and higher Ets-1 expression compared to ex adenoma carcinomas. These findings support the hypothesis that there are differences in the carcinogenesis of these tumors.
Literature
1.
Vãlean S, Mircea PA, Oprea L (2006) Trends of mortality rates from gastric cancer and colorectal cancer in Romania, 1955–2003. J Gastrointestin Liver Dis 15(2):111–115PubMed
2.
Hamilton RS, Aaltonen AL (2000) Pathology and genetics, toumors of the digestive system. IARC Press, Lyon
3.
Pećina-Šlaus N (2003) Tumor suppressor gene E-cadherin and its role in normal and malignant cells. Cancer Cell Int 3:17PubMed
4.
Day MR, Hao X, Mohammad I, Daszak P, Talbot IC, Forbes A (1999) Changes in the expression of syndecan-1 in the colorectal adenoma-carcinoma sequence. Virchows Arch 434:121–125CrossRefPubMed
5.
6.
Nakayama T, Masahiro I, Akira O, Shinji N, Ichiro S (2001) Expression of the ets-1 Proto-Oncogene in human colorectal carcinoma. Mod Pathol 14(5):415–422CrossRefPubMed
7.
Arun S, Watson KD (2005) Ets transcription factors and their emerging roles in human cancer. Eur J Cancer 41:2462–2478
8.
Nosho K, Yoshiday M, Yamamoto M, Taniguchi H, Adachi Y, Mikami M, Hinodal Y, Imai K (2005) Association of Ets-related transcriptional factor E1AF expression with overexpression of matrix metalloproteinases, COX-2 and iNOS in the early stage of colorectal carcinogenesis. Carcinogenesis 26(5):892–899CrossRefPubMed
9.
Behrens P, Mathiak M, Mangold E, Kirdorf S, Wellmann A, Fogt F, Rothe M, Florin A, Wernert N (2003) Stromal expression of invasion-promoting matrix-degrading proteases MMP-1 and -9 and the Ets-1 transcription factor in HNPCC carcinomas and sporadic colorectal cancers. Int J Cancer 107:183–188CrossRefPubMed
10.
Khoursheed MA, Mathew TC, Makar RR, Louis S, Asfar SK, Al-Sayer HM, Dashti HM, Al-Bader A (2003) Expression of E-cadherin in human colorectal cancer. Surg J R Coll Surg Edinb Irel 86–91
11.
Elzagheid A, Ålgars A, Bendardaf R, Lamlum H, Ristamaki R, Collan Y, Syrjanen K, Pyrhonen S (2006) E-cadherin expression pattern in primary colorectal carcinomas and their metastases reflects disease outcome. World J Gastroenterol 12(27):4304–4309PubMed
12.
Fujiya M, Watari J, Ashida T, Honda M, Tanabe H, Fujiki T, Saitoh Y, Kohgo Y (2001) Reduced expression of syndecan-1 affects metastatic potential and clinical outcome in patients with colorectal cancer. Jpn. J Cancer Res 192:1074–1081
13.
Lundin M, Nordling S, Lundin J, Isola J, Wiksten JP, Haglund C (2005) Epithelial syndecan-1 expression is associated with stage and grade in colorectal cancer. Oncology 68:306–313CrossRefPubMed
14.
Rosai J (2004) Rosai and Ackerman`s surgical pathology, 9th edn. Mosby, London
15.
Geller SA, Dhall D, Alsabeh R (2008) Application of immunohistochemistry to liver and gastrointestinal neoplasms: liver, stomach, colon, and pancreas. Arch Pathol Lab Med 132:490–499PubMed
16.
Wlodarczyk J, Bethke B, Mueller E, Stolte M, Mueller J (2001) A comparative study of E-cadherin and stromelysin-3 expression in de novo and ex adenoma carcinoma of the colorectum. Virchows Arch 439:756–761PubMed
17.
Batistatou A, Charalabopoulos AK, Scopa CD, Nakanishi Y, Kappas A, Hirohashi S, Agnantis NJ, Charalabopoulos K (2006) Expression patterns of dysadherin and E-cadherin in lymph node metastases of colorectal carcinoma. Virchows Arch 448:763–767CrossRefPubMed
18.
Peretti T, Waisberg J, Mader AM, Matos L, Costa R, Conceicao G, Lopes A, Nader H, Pinhal M (2008) Heparanase-2, syndecan-1, and extracellular matrix remodeling in colorectal carcinoma. Eur J Gastroenterol & Hepatol 20:756–765CrossRef
19.
Gottardi JC, Wong E, Gumbiner MB (2001) E-Cadherin suppresses cellular transformation by inhibiting β-catenin signaling in an adhesion-independent manner. J Cell Biol 153(5):1049–1059CrossRefPubMed
20.
Qinglang L, Pyong WP, Wilson LC, Parks CW (2002) Matrilysin shedding of syndecan-1 regulates Chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 111:635–646CrossRef
21.
Fitzgerald LM, Wang Z, Park WP, Murphy G, Bernfield M (2000) Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase. J. Cell Biol 148(4):811–824CrossRefPubMed
22.
Hashimoto Y, Skacel M, Adams JC (2008) Association of loss of epithelial syndecan-1 with stage and local metastasis of colorectal adenocarcinomas: an immunohistochemical study of clinically annotated tumors. BMC Cancer 8(185):1–7
23.
Kwak JM, Min BW, Lee JH, Choi JS, Lee SI, Park SS, Kim J, Um JW, Kim SH, Moon HY (2007) The prognostic significance of E-cadherin and liver intestine-cadherin expression in colorectal cancer. Dis Colon Rectum 50:1873–1880CrossRefPubMed
24.
Dilek F, Topak N, Aktepe F, Sahin O, Turel KS, Sahin DA, Dilek ON (2008) E-cadherin, β-catenin adhesion complex and relation to matrilysin expression in pT3 rectosigmoid cancers. Pathol Res Practice 204(11):809–815CrossRef
25.
Tetsuji T, Koji M, Tsuyoshi H (2006) Colorectal cancer: genetics of development and metastasis. J Gastroenterology 41:185–192CrossRef
26.
Ortega P, Moran A, de Juan C, Frias C, Hernandez S, Lopez-Asenjo J-A, Sanchez-Pernaute A, Torres A, Iniesta P, Benito M (2008) Differential Wnt pathway gene expression and E-cadherin truncation in sporadic colorectal cancers with and without microsatellite instability. Clin Cancer Res 14(4):995–1001CrossRefPubMed
27.
28.
McGuire KJ, Qinglang L, Parks CW (2003) Matrilysin (Matrix Metalloproteinase-7) mediates E-Cadherin ectodomain shedding in injured lung epithelium. Am J Pathol 162(6):1831–1843PubMed
Metadata
Title
An Immunohistochemical Study of Colon Adenomas and Carcinomas: E-cadherin, Syndecan-1, Ets-1
Authors
Zsuzsanna Pap
Zoltán Pávai
Lóránd Dénes
Ilona Kovalszky
János Jung
Publication date
01-12-2009
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 4/2009
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-009-9157-x

Other articles of this Issue 4/2009

Pathology & Oncology Research 4/2009 Go to the issue

Original Paper

Lung Tumor Development in the Presence of Sphingosine 1-phosphate Agonist FTY720

OriginalPaper

Diagnostic Concordance in Reporting Breast Needle Core Biopsies using the B Classification—A Panel in Italy

OriginalPaper

Differential Expression of Notch Family Members in Astrocytomas and Medulloblastomas

Original Paper

GABA Receptor Expression in Benign and Malignant Thyroid Tumors

OriginalPaper

Post-Translational Regulation of Cathepsin B, but not of Other Cysteine Cathepsins, Contributes to Increased Glioblastoma Cell Invasiveness In Vitro

Case Report

Adult Extrarenal Wilms’ Tumor Mimicking Mixed Epithelial and Stromal Tumor in the Retroperitoneum: A Case Report with Immunohistochemical Study and Review of the Literature
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits